Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neonatal Withdrawal Syndrome Clear all
Completed Not applicable Interventional Results available

Weighted Blankets With Infants With NAS

NCT03113656
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Weighted Blanket, Non-Weighted Blanket
Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
37 Weeks and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Jul 23, 2026, 1:15 AM EDT
Terminated Phase 4 Interventional Results available

Clonidine as Adjunct to Morphine for Neonatal Abstinence Syndrome

NCT03762317
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Clonidine, Placebo
Drug
Lead sponsor
Hennepin County Medical Center, Minneapolis
Other
Eligibility
36 Weeks to 45 Weeks
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Jul 23, 2026, 1:15 AM EDT
Terminated Phase 2 Interventional Results available

Methadone Demonstration Project With Neonatal Intensive Care Unit Infants Diagnosed With Neonatal Abstinence Syndrome

NCT03134703
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Methadone, Morphine
Drug
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
Up to 72 Hours
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Jul 23, 2026, 1:15 AM EDT
Completed No phase listed Observational

Utility of Psychosocial Intervention in Improving Outcome for Methadone-exposed Infants and Their Mothers

NCT01889121
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Structured psychosocial intervention
Behavioral
Lead sponsor
Dr. Henry Akinbi
Other
Eligibility
Female only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 27, 2013 · Synced Jul 23, 2026, 1:15 AM EDT
Completed Not applicable Interventional

Assessing the Effects of Auricular Acupressure on Newborns With NAS

NCT03890562
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Auricular acupressure
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Up to 2 Months
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Jul 23, 2026, 1:15 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Trial to Shorten Pharmacologic Treatment of Newborns With Neonatal Opioid Withdrawal Syndrome (NOWS)

NCT04214834
View directory record Official record
Conditions
Neonatal Opioid Withdrawal Syndrome
Interventions
Morphine, Methadone
Drug
Lead sponsor
Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program
Network
Eligibility
36 Weeks and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
24
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 23, 2026, 1:15 AM EDT
Completed Phase 3 Interventional Results available

Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome

NCT01452789
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
sublingual buprenorphine, oral morphine
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Jul 23, 2026, 1:15 AM EDT
Completed Not applicable Interventional Results available

Acupuncture in Neonatal Abstinence Syndrome (NAS) Babies

NCT02062151
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Acupuncture
Other
Lead sponsor
University of South Florida
Other
Eligibility
1 Day to 3 Months
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Jul 23, 2026, 1:15 AM EDT
Completed Phase 2 Interventional Results available

Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women

NCT01965704
View directory record Official record
Conditions
Narcotic Addiction, Neonatal Abstinence Syndrome
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
Up to 45 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
8
States / cities
San Francisco, California • San Jose, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Jul 23, 2026, 1:15 AM EDT
Completed Phase 3 Interventional

Optimizing Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome (OPTimize NOW): A Symptom-Based Dosing Approach

NCT05980260
View directory record Official record
Conditions
Neonatal Opiate Withdrawal Syndrome
Interventions
Symptom-based Dosing Approach, Scheduled Opioid Taper Approach
Other
Lead sponsor
HELP for NOWS Consortium
Network
Eligibility
1 Hour to 48 Hours
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Wilmington, Delaware + 16 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 23, 2026, 1:15 AM EDT
Recruiting Not applicable Interventional

Effect of Music Therapy on Infants With Neonatal Abstinence Syndrome

NCT03533985
View directory record Official record
Conditions
NAS
Interventions
Song of Kin, Gato box, Ocean disc, Contingent singing, Tonal Vocal holding, Muted shaker
Behavioral · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
28 Weeks and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
6
States / cities
New Orleans, Louisiana • Hackensack, New Jersey • New Hyde Park, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 23, 2026, 1:15 AM EDT
Terminated Phase 3 Interventional

Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis

NCT02258867
View directory record Official record
Conditions
Behcet's Disease Uveitis
Interventions
Placebo, Gevokizumab
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Santa Ana, California • Chicago, Illinois • Ellsworth, Maine + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Jul 23, 2026, 1:15 AM EDT
Completed Phase 3 Interventional Results available

Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)

NCT00288704
View directory record Official record
Conditions
Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria, Muckle-Wells Syndrome (MWS), Genetic Diseases, Inborn
Interventions
rilonacept 160 mg, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
24
States / cities
Little Rock, Arkansas • Palm Desert, California • Upland, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2011 · Synced Jul 23, 2026, 1:15 AM EDT
Completed Phase 1 Interventional

Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines

NCT01671410
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
oral morphine, sublingual buprenorphine
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Jul 23, 2026, 1:15 AM EDT
Completed Phase 1 Interventional

Buprenorphine for the Treatment of Neonatal Abstinence Syndrome

NCT00521248
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
buprenorphine, Oral morphine solution
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 23, 2026, 1:15 AM EDT
Completed No phase listed Observational

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study

NCT03911466
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions
Buprenorphine Injection, Buprenorphine Sublingual Product
Drug
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
12
States / cities
Jacksonville, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jul 23, 2026, 1:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure

NCT03608696
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome
Interventions
Buprenorphine
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Up to 4 Weeks
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Jul 23, 2026, 1:15 AM EDT
Active, not recruiting Phase 4 Interventional

Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy

NCT03092011
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Clonidine, Morphine Sulfate
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
Up to 10 Days
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Jul 23, 2026, 1:15 AM EDT
Completed Phase 2 Interventional Results available

Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome

NCT03670160
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Phenobarbital, Clonidine
Drug
Lead sponsor
University of Tennessee Medical Center
Other
Eligibility
35 Weeks and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Jul 23, 2026, 1:15 AM EDT
Terminated Phase 3 Interventional Results available

Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents

NCT03567291
View directory record Official record
Conditions
Tourette Syndrome
Interventions
TEV-50717, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
33
States / cities
Dothan, Alabama • Rogers, Arkansas • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Jul 23, 2026, 1:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Testing an Arts-based Program to Reduce Nurse Stigma Towards Perinatal Substance Use

NCT06410287
View directory record Official record
Conditions
Nurse's Role, Stigma, Social, Implicit Bias
Interventions
ArtSpective
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Saint Cloud, Minnesota • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jul 23, 2026, 1:15 AM EDT
Recruiting No phase listed Observational

Target Trial Emulation for Pharmacologic Treatment of Neonatal Opioid Withdrawal Syndrome

NCT07278375
View directory record Official record
Conditions
Neonatal Opioid Withdrawal Syndrome
Interventions
Not listed
Lead sponsor
HELP for NOWS Consortium
Network
Eligibility
0 Minutes and older
Enrollment
796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Wilmington, Delaware + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 23, 2026, 1:15 AM EDT
Completed Not applicable Interventional

Physiology and Therapeutic Management of Neonatal Abstinence Syndrome

NCT02768844
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Stochastic Vibrotactile Stimulation (SVS), Control
Device · Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
1 Day to 1 Year
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Jul 23, 2026, 1:15 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Neonatal Abstinence Syndrome

NCT01723722
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Methadone, Diluted Deodorized Tincture of Opium
Drug
Lead sponsor
Eastern Maine Medical Center
Other
Eligibility
1 Day to 6 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bangor, Maine
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Jul 23, 2026, 1:15 AM EDT